Renal antiporter ClC-5 regulates collagen I/IV through the β-catenin pathway and lysosomal degradation
Life Science Alliance · 2024-07 · 7 (7) · e202302444
DOI: 10.26508/lsa.202302444 ↗Kurz gefasst
Fachartikel in der Zeitschrift Life Science Alliance, online erschienen am 26.04.2024. Verfasst von Mònica Durán und 7 weiteren Autor:innen. Beteiligte Einrichtung: Renal Physiopathology Group, Vall d'Hebron Research Institute (VHIR), Barcelona, Spain. Hauptthemen laut MEDLINE: Chloride Channels, Lysosomes, beta Catenin, Fibrosis. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministerio de Ciencia e Innovación, MEC | Instituto de Salud Carlos III, Sociedad Española de Nefrología.
Abstract (Originalsprache)
Mutations in Cl − /H + antiporter ClC-5 cause Dent’s disease type 1 (DD1), a rare tubulopathy that progresses to renal fibrosis and kidney failure. Here, we have used DD1 human cellular models and renal tissue from DD1 mice to unravel the role of ClC-5 in renal fibrosis. Our results in cell systems have shown that ClC-5 deletion causes an increase in collagen I (Col I) and IV (Col IV) intracellular levels by promoting their transcription through the β-catenin pathway and impairing their lysosomal-mediated degradation. Increased production of Col I/IV in ClC-5–depleted cells ends up in higher release to the extracellular medium, which may lead to renal fibrosis. Furthermore, our data have revealed that 3-mo-old mice lacking ClC-5 ( Clcn5 +/− and Clcn5 −/− ) present higher renal collagen deposition and fibrosis than WT mice. Altogether, we describe a new regulatory mechanism for collagens’ production and release by ClC-5, which is altered in DD1 and provides a better understanding of disease progression to renal fibrosis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Renal Physiopathology Group, Vall d'Hebron Research Institute (VHIR), Barcelona, Spain.
- Pediatric Nephrology Department, Vall d'Hebron University Hospital, Barcelona, Spain.
- Pediatrics Department, School of Medicine, Autonomous University of Barcelona (UAB), Bellaterra, Spain.
- Department of Pathology, Vall d'Hebron University Hospital, Barcelona, Spain.
- Wake Forest Institute for Regenerative Medicine, Winston-Salem, NC, USA.
- Renal Physiopathology Group, Vall d'Hebron Research Institute (VHIR), Barcelona, Spain ana.meseguer@vhir.org.
ORCID-Profile: Andrea Casal-Pardo, Baisong Lu, Anna Meseguer, Gerard Cantero-Recasens
Förderung
- Ministerio de Ciencia e Innovación
- MEC | Instituto de Salud Carlos III
- Sociedad Española de Nefrología
- Mizutani Foundation for Glycoscience
- Government of Catalonia | Agència de Gestió d’Ajuts Universitaris i de Recerca
Zitieren
APA
Durán, M., Ariceta, G., Semidey, M. E., Castells-Esteve, C., Casal-Pardo, A., Lu, B., Meseguer, A., & Cantero-Recasens, G. (2024). Renal antiporter ClC-5 regulates collagen I/IV through the β-catenin pathway and lysosomal degradation. Life Science Alliance, 7(7), e202302444. https://doi.org/10.26508/lsa.202302444
Vancouver
Durán M, Ariceta G, Semidey ME, Castells-Esteve C, Casal-Pardo A, Lu B, et al. Renal antiporter ClC-5 regulates collagen I/IV through the β-catenin pathway and lysosomal degradation. Life Science Alliance. 2024;7(7):e202302444. doi:10.26508/lsa.202302444
BibTeX
@article{Durn2024,
author = {Durán, Mònica and Ariceta, Gema and Semidey, Maria E and Castells-Esteve, Carla and Casal-Pardo, Andrea and Lu, Baisong and Meseguer, Anna and Cantero-Recasens, Gerard},
title = {Renal antiporter ClC-5 regulates collagen I/IV through the β-catenin pathway and lysosomal degradation},
journal = {Life Science Alliance},
year = {2024},
volume = {7},
number = {7},
pages = {e202302444},
doi = {10.26508/lsa.202302444}
}
EUVIMED